Therapeutics
Immunotherapy (active)
- Study completed / Planned end date
- Planned end date unavailable
- Study aborted
| Immunotherapy (active) | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AADvac1 |
Phase 1, Phase 2
|
|||||||||||||||||||||||||||
| ABvac40 |
Phase 2
|
|||||||||||||||||||||||||||
| ACI-24.060 |
Phase 1/2
|
|||||||||||||||||||||||||||
| AN-1792 |
Phase 2
|
|||||||||||||||||||||||||||
| Affitope AD02 |
Phase 2
|
|||||||||||||||||||||||||||
| Amilomotide |
Phase 2
|
|||||||||||||||||||||||||||
| Vanutide cridificar |
Phase 2
|